Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer
Clinical trial NCT05177068 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05177068
- Sponsor
- Henan Cancer Hospital
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-13
- Primary completion
- 2024-10-16
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.